Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer.
CA125
HGSOC
annexin A2
biomarkers
early detection
ovarian cancer
plasma
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
04 Jan 2021
04 Jan 2021
Historique:
received:
18
11
2020
revised:
14
12
2020
accepted:
22
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
Ovarian cancer (OC) is commonly diagnosed at advanced stage when prognosis is poor. Consequently, there is an urgent clinical need to identify novel biomarkers for early detection to improve survival. We examined the diagnostic value of the calcium phospholipid binding protein annexin A2 (ANXA2), which plays an important role in OC metastasis. Annexin A2 plasma levels in patients with high grade serous OC (
Identifiants
pubmed: 33406648
pii: diagnostics11010069
doi: 10.3390/diagnostics11010069
pmc: PMC7823988
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Oncol. 2012 Oct;127(1):75-82
pubmed: 22750127
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Int J Cancer. 2019 May 1;144(9):2074-2081
pubmed: 30125343
Heliyon. 2019 Dec 05;5(12):e02826
pubmed: 31867451
Tumour Biol. 2016 Jan;37(1):211-6
pubmed: 26189841
Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11
pubmed: 26970494
Carcinogenesis. 2013 Mar;34(3):595-604
pubmed: 23188673
Biomed Pharmacother. 2015 Feb;69:237-41
pubmed: 25661364
Cancer Biomark. 2015;15(2):205-11
pubmed: 25519022
Obstet Gynecol. 2011 Jun;117(6):1289-1297
pubmed: 21606739
APMIS. 1994 Sep;102(9):667-73
pubmed: 7946269
Cancer Microenviron. 2011 Aug;4(2):199-208
pubmed: 21909879
N Engl J Med. 2009 Jul 9;361(2):170-7
pubmed: 19587342
Adv Exp Med Biol. 2020;1219:355-363
pubmed: 32130708
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842290
Chang Gung Med J. 2003 Sep;26(9):695-9
pubmed: 14651169
Hum Reprod. 1989 Jan;4(1):1-12
pubmed: 2651469
Biochim Biophys Acta. 2000 Mar 7;1477(1-2):215-30
pubmed: 10708859
Anticancer Res. 2017 May;37(5):2727-2734
pubmed: 28476852
J Surg Oncol. 2000 Dec;75(4):264-5
pubmed: 11135268
Transl Res. 2016 May;171:83-95.e1-2
pubmed: 26925708
J Natl Compr Canc Netw. 2008 Sep;6(8):795-802
pubmed: 18926090
Oncotarget. 2013 Aug;4(8):1199-211
pubmed: 23945256
Vascul Pharmacol. 2011 Mar-Jun;54(3-6):59-67
pubmed: 21440088
Int J Mol Med. 2009 Dec;24(6):765-71
pubmed: 19885616
Int J Cancer. 2011 Apr 1;128(7):1570-84
pubmed: 20521251
Ann Clin Biochem. 2017 Jul;54(4):463-471
pubmed: 27496793
Blood. 2006 Apr 15;107(8):3342-9
pubmed: 16373665
Med Sci Monit. 2014 Oct 03;20:1801-7
pubmed: 25287627
Proteomics. 2013 Nov;13(21):3145-56
pubmed: 24019232
J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51
pubmed: 8411259
Gynecol Oncol. 2009 Jan;112(1):40-6
pubmed: 18851871
FEBS J. 2008 Oct;275(19):4810-23
pubmed: 18721140